Evidence map›Paper›PMID 33692101›Full record

ArticleScience advances2021

α-Synuclein-induced Kv4 channelopathy in mouse vagal motoneurons drives nonmotor parkinsonian symptoms.

Wei-Hua Chiu, Lora Kovacheva, Ruth E Musgrove, Hadar Arien-Zakay, James B Koprich, Jonathan M Brotchie, Rami Yaka, Danny Ben-Zvi, Menachem Hanani, Jochen Roeper and 1 more

Open access · goldAbstract read
In one paragraph

Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. NaJournal of neural transmission (Vienna, Austria : 1996) · 2021
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Wei-Hua ChiuDepartment of Medical Neurobiology, Institute of Medical Research Israel-Canada, The Faculty of Medicine, The Hebrew University of Jerusalem, 9112102 Jerusalem, Israel.ORCID 0000-0001-5724-5680
Lora KovachevaInstitute of Neurophysiology, Neuroscience Center, Goethe University, 60590 Frankfurt, Germany.ORCID 0000-0001-6999-1533
Ruth E MusgroveDepartment of Medical Neurobiology, Institute of Medical Research Israel-Canada, The Faculty of Medicine, The Hebrew University of Jerusalem, 9112102 Jerusalem, Israel.ORCID 0000-0002-8695-8548
Hadar Arien-ZakaySchool of Pharmacy, Institute for Drug Research, The Faculty of Medicine, The Hebrew University of Jerusalem, 9112102 Jerusalem, Israel.
James B KoprichKrembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON M5T 2S8, Canada.
Jonathan M BrotchieKrembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON M5T 2S8, Canada.ORCID 0000-0003-2337-0816
Rami YakaSchool of Pharmacy, Institute for Drug Research, The Faculty of Medicine, The Hebrew University of Jerusalem, 9112102 Jerusalem, Israel.ORCID 0000-0003-2372-2957
Danny Ben-ZviDepartment of Developmental Biology and Cancer Research, Institute of Medical Research Israel-Canada, The Faculty of Medicine, The Hebrew University of Jerusalem, 9112102 Jerusalem, Israel.ORCID 0000-0002-8697-9744
Menachem HananiDepartment of Medical Neurobiology, Institute of Medical Research Israel-Canada, The Faculty of Medicine, The Hebrew University of Jerusalem, 9112102 Jerusalem, Israel.
Jochen RoeperInstitute of Neurophysiology, Neuroscience Center, Goethe University, 60590 Frankfurt, Germany.ORCID 0000-0003-2145-8742
Joshua A GoldbergDepartment of Medical Neurobiology, Institute of Medical Research Israel-Canada, The Faculty of Medicine, The Hebrew University of Jerusalem, 9112102 Jerusalem, Israel. joshua.goldberg2@mail.huji.ac.il.ORCID 0000-0002-5740-4087
Hebrew University of Jerusalem · ILGoethe University Frankfurt · DEUniversity Health Network · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

No disease-modifying therapy is currently available for Parkinson's disease (PD), the second most common neurodegenerative disease. The long nonmotor prodromal phase of PD is a window of opportunity for early detection and intervention. However, we lack the pathophysiological understanding to develop selective biomarkers and interventions. By using a mutant α-synuclein selective-overexpression mouse model of prodromal PD, we identified a cell-autonomous selective Kv4 channelopathy in dorsal motor nucleus of the vagus (DMV) neurons. This functional remodeling of intact DMV neurons leads to impaired pacemaker function in vitro and in vivo, which, in turn, reduces gastrointestinal motility, a common early symptom of prodromal PD. We identify a chain of events from α-synuclein via a biophysical dysfunction of a specific neuronal population to a clinically relevant prodromal symptom. These findings will facilitate the rational design of clinical biomarkers to identify people at risk for developing PD.

Indexed as

ChannelopathiesNeurodegenerative DiseasesParkinson Diseasealpha-SynucleinAnimalsHumansMiceMotor Neuronsalpha-Synuclein

Identifiers

PMID33692101
PMCPMC7946367
OpenAlexW3133918164

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.